Symbols / BIIB
BIIB Chart
About
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Gen | Market Cap | 27.13B |
| Enterprise Value | 29.97B | Income | 1.29B | Sales | 9.89B |
| Book/sh | 124.36 | Cash/sh | 26.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | 7500 | IPO | — |
| P/E | 21.06 | Forward P/E | 11.38 | PEG | — |
| P/S | 2.74 | P/B | 1.49 | P/C | — |
| EV/EBITDA | 8.32 | EV/Sales | 3.03 | Quick Ratio | 1.70 |
| Current Ratio | 2.68 | Debt/Eq | 36.47 | LT Debt/Eq | — |
| EPS (ttm) | 8.78 | EPS next Y | 16.24 | EPS Growth | — |
| Revenue Growth | -7.10% | Earnings | 2026-04-30 | ROA | 6.14% |
| ROE | 7.39% | ROIC | — | Gross Margin | 78.95% |
| Oper. Margin | 19.64% | Profit Margin | 13.07% | Shs Outstand | 146.76M |
| Shs Float | 146.28M | Short Float | 4.00% | Short Ratio | 2.70 |
| Short Interest | — | 52W High | 202.41 | 52W Low | 110.04 |
| Beta | 0.14 | Avg Volume | 1.72M | Volume | 772.83K |
| Target Price | $205.67 | Recom | Buy | Prev Close | $188.08 |
| Price | $184.87 | Change | -1.71% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$205.67
Mean price target
2. Current target
$184.87
Latest analyst target
3. DCF / Fair value
$243.08
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$184.87
Low
$143.00
High
$260.00
Mean
$205.67
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-20 | init | Barclays | — → Equal-Weight | $185 |
| 2026-02-10 | main | Wedbush | Neutral → Neutral | $187 |
| 2026-02-09 | main | JP Morgan | Neutral → Neutral | $230 |
| 2026-02-09 | main | Canaccord Genuity | Buy → Buy | $230 |
| 2026-02-09 | main | BMO Capital | Market Perform → Market Perform | $196 |
| 2026-02-09 | main | TD Cowen | Buy → Buy | $215 |
| 2026-02-09 | main | Citigroup | Neutral → Neutral | $215 |
| 2026-02-09 | main | RBC Capital | Outperform → Outperform | $233 |
| 2026-02-09 | main | Guggenheim | Buy → Buy | $246 |
| 2026-02-09 | main | Wells Fargo | Equal-Weight → Equal-Weight | $200 |
| 2026-02-09 | main | Truist Securities | Hold → Hold | $193 |
| 2026-02-09 | main | Wedbush | Neutral → Neutral | $187 |
| 2026-02-09 | main | HC Wainwright & Co. | Buy → Buy | $228 |
| 2026-02-09 | main | Piper Sandler | Neutral → Neutral | $177 |
| 2026-01-30 | main | Oppenheimer | Outperform → Outperform | $225 |
| 2026-01-27 | main | Citigroup | Neutral → Neutral | $185 |
| 2026-01-08 | main | Truist Securities | Hold → Hold | $190 |
| 2026-01-07 | main | Citigroup | Neutral → Neutral | $180 |
| 2025-12-12 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $156 |
| 2025-12-10 | main | Wells Fargo | Equal-Weight → Equal-Weight | $190 |
- Is BIIB stock a buy on dips - Weekly Volume Report & Reliable Entry Point Trade Alerts - Naître et grandir Sat, 07 Mar 2026 19
- What Makes Biogen (BIIB) an Attractive Long-Term Holding? - Yahoo Finance hu, 05 Mar 2026 13
- Biogen tests once-yearly SMA drug as US reviews high-dose SPINRAZA - Stock Titan hu, 05 Mar 2026 12
- Biogen Inc. $BIIB Shares Sold by Fisher Asset Management LLC - MarketBeat Wed, 04 Mar 2026 09
- Biogen Inc (BIIB) Shares Gap Down to $181.74 on Mar 6 - GuruFocus Fri, 06 Mar 2026 17
- How Investors Are Reacting To Biogen (BIIB) Advancing Salanersen And Expanding Its SMA Franchise - simplywall.st Fri, 06 Mar 2026 19
- Street Watch: Why BIIB stock could outperform in 2026 - Weekly Investment Recap & Daily Price Action Insights - Naître et grandir Sat, 07 Mar 2026 02
- Stoke Therapeutics and Biogen Announce Promising Results for Zorevunersen in Treating Dravet Syndrome, Supporting Phase 3 EMPEROR Study - Quiver Quantitative Wed, 04 Mar 2026 22
- How One Drug Heavy-Lifted Biogen's Fourth-Quarter Beat - Investor's Business Daily Fri, 06 Feb 2026 08
- Why Biogen Stock Surged Almost 9% Higher on Friday - The Motley Fool Fri, 06 Feb 2026 08
- Strong Cash Yield: Is Biogen Stock A Buy? - Trefis Sat, 17 Jan 2026 08
- BIIB Stock: Is Biogen Still A Buy After The 14% Spike? - Forbes Fri, 03 Oct 2025 07
- Biogen (BIIB) Stock Trades Up, Here Is Why - Yahoo Finance Fri, 19 Dec 2025 08
- TD Asset Management Inc Increases Stock Holdings in Biogen Inc. $BIIB - MarketBeat Sun, 01 Mar 2026 12
- Biogen (BIIB) Valuation Check As Shares Trade Below Analyst Targets And Long Term Returns Stay Under Pressure - Yahoo Finance Mon, 26 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 3 | 585.0 | — | Purchase at price 195.04 per share. | MURPHY NICOLE | Officer | — | 2026-02-12 00:00:00 | D |
| 1 | 2660 | 531548.0 | — | Sale at price 199.83 per share. | SINGHAL PRIYA | Officer | — | 2026-02-09 00:00:00 | D |
| 2 | 7183 | nan | — | — | GREGORY GINGER | Officer | — | 2026-02-06 00:00:00 | D |
| 3 | 9046 | nan | — | — | ALEXANDER SUSAN H | Officer | — | 2026-02-06 00:00:00 | D |
| 4 | 6889 | nan | — | — | IZZAR RACHID | Officer | — | 2026-02-06 00:00:00 | D |
| 5 | 8725 | nan | — | — | MURPHY NICOLE | Officer | — | 2026-02-06 00:00:00 | D |
| 6 | 5080 | nan | — | — | KEENEY ADAM JAMES | Officer | — | 2026-02-06 00:00:00 | D |
| 7 | 3258 | nan | — | — | GROGAN JANE | Officer | — | 2026-02-06 00:00:00 | D |
| 8 | 1079 | nan | — | — | GODBOUT SEAN | Officer | — | 2026-02-06 00:00:00 | D |
| 9 | 6900 | nan | — | — | SINGHAL PRIYA | Officer | — | 2026-02-06 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -134.59M | -39.79M | -60.41M | 150.88M |
| TaxRateForCalcs | 0.17 | 0.14 | 0.10 | 0.18 |
| NormalizedEBITDA | 3.40B | 3.11B | 2.62B | 3.50B |
| TotalUnusualItems | -794.70M | -277.00M | -580.90M | 857.30M |
| TotalUnusualItemsExcludingGoodwill | -794.70M | -277.00M | -580.90M | 857.30M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 1.29B | 1.63B | 1.16B | 3.05B |
| ReconciledDepreciation | 779.90M | 673.20M | 494.80M | 518.40M |
| ReconciledCostOfRevenue | 2.14B | 2.08B | 2.28B | 2.13B |
| EBITDA | 2.60B | 2.83B | 2.04B | 4.36B |
| EBIT | 1.82B | 2.16B | 1.54B | 3.84B |
| NetInterestIncome | -142.50M | -182.70M | 29.60M | -157.30M |
| InterestExpense | 267.50M | 250.30M | 246.90M | 246.60M |
| InterestIncome | 125.00M | 67.60M | 276.50M | 89.30M |
| NormalizedIncome | 1.95B | 1.87B | 1.68B | 2.34B |
| NetIncomeFromContinuingAndDiscontinuedOperation | 1.29B | 1.63B | 1.16B | 3.05B |
| TotalExpenses | 7.42B | 7.40B | 7.99B | 7.27B |
| TotalOperatingIncomeAsReported | 2.84B | |||
| DilutedAverageShares | 147.10M | 145.90M | 145.60M | 146.00M |
| BasicAverageShares | 146.50M | 145.60M | 144.70M | 145.30M |
| DilutedEPS | 8.79 | 11.18 | 7.97 | 20.87 |
| BasicEPS | 8.83 | 11.21 | 8.02 | 20.96 |
| DilutedNIAvailtoComStockholders | 1.29B | 1.63B | 1.16B | 3.05B |
| NetIncomeCommonStockholders | 1.29B | 1.63B | 1.16B | 3.05B |
| NetIncome | 1.29B | 1.63B | 1.16B | 3.05B |
| MinorityInterests | 0.00 | 0.00 | -400.00K | 85.30M |
| NetIncomeIncludingNoncontrollingInterests | 1.29B | 1.63B | 1.16B | 2.96B |
| NetIncomeContinuousOperations | 1.29B | 1.63B | 1.16B | 2.96B |
| EarningsFromEquityInterestNetOfTax | 0.00 | 0.00 | 2.60M | 34.90M |
| TaxProvision | 263.60M | 273.80M | 135.30M | 632.80M |
| PretaxIncome | 1.56B | 1.91B | 1.30B | 3.59B |
| OtherIncomeExpense | -770.00M | -191.70M | -580.50M | 847.20M |
| OtherNonOperatingIncomeExpenses | 24.70M | 85.30M | 400.00K | -10.10M |
| SpecialIncomeCharges | -746.40M | -145.70M | -239.30M | 1.17B |
| GainOnSaleOfPPE | 0.00 | 0.00 | 503.70M | 0.00 |
| GainOnSaleOfBusiness | 0.00 | 0.00 | 1.51B | 0.00 |
| OtherSpecialCharges | 611.30M | 87.80M | 20.50M | 917.00M |
| ImpairmentOfCapitalAssets | 52.90M | 0.00 | 0.00 | |
| RestructuringAndMergernAcquisition | 82.20M | 57.90M | 218.80M | -78.00M |
| GainOnSaleOfSecurity | -48.30M | -131.30M | -341.60M | -312.80M |
| NetNonOperatingInterestIncomeExpense | -142.50M | -182.70M | 29.60M | -157.30M |
| InterestExpenseNonOperating | 267.50M | 250.30M | 246.90M | 246.60M |
| InterestIncomeNonOperating | 125.00M | 67.60M | 276.50M | 89.30M |
| OperatingIncome | 2.47B | 2.28B | 1.85B | 2.90B |
| OperatingExpense | 5.02B | 5.09B | 5.45B | 4.99B |
| OtherOperatingExpenses | 290.20M | 254.40M | 218.80M | -7.40M |
| DepreciationAmortizationDepletionIncomeStatement | 515.00M | 446.70M | 240.60M | 365.90M |
| DepreciationAndAmortizationInIncomeStatement | 515.00M | 446.70M | 240.60M | 365.90M |
| Amortization | 515.00M | 446.70M | 240.60M | 365.90M |
| AmortizationOfIntangiblesIncomeStatement | 515.00M | 446.70M | 240.60M | 365.90M |
| ResearchAndDevelopment | 1.78B | 1.98B | 2.45B | 2.23B |
| SellingGeneralAndAdministration | 2.43B | 2.40B | 2.55B | 2.40B |
| GrossProfit | 7.49B | 7.37B | 7.30B | 7.90B |
| CostOfRevenue | 2.40B | 2.31B | 2.53B | 2.28B |
| TotalRevenue | 9.89B | 9.68B | 9.84B | 10.17B |
| OperatingRevenue | 9.89B | 9.68B | 9.84B | 9.69B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 23.80M | 23.80M | 23.80M | 23.80M |
| PreferredSharesNumber | 8.00K | 8.00K | 8.00K | 8.00K |
| OrdinarySharesNumber | 146.80M | 145.72M | 144.90M | 144.00M |
| ShareIssued | 170.60M | 169.52M | 168.70M | 167.80M |
| NetDebt | 3.28B | 3.92B | 5.89B | 2.86B |
| TotalDebt | 6.58B | 6.63B | 7.34B | 6.61B |
| TangibleBookValue | 2.59B | 545.90M | 217.20M | 5.80B |
| InvestedCapital | 24.54B | 23.01B | 21.74B | 19.68B |
| WorkingCapital | 5.62B | 1.93B | 3.42B | 6.52B |
| NetTangibleAssets | 2.59B | 545.90M | 217.20M | 5.80B |
| CapitalLeaseObligations | 290.40M | 334.50M | 400.00M | 333.00M |
| CommonStockEquity | 18.26B | 16.72B | 14.80B | 13.40B |
| TotalCapitalization | 24.54B | 21.26B | 21.59B | 19.68B |
| TotalEquityGrossMinorityInterest | 18.26B | 16.72B | 14.80B | 13.39B |
| MinorityInterest | 0.00 | -9.50M | 63.50M | |
| StockholdersEquity | 18.26B | 16.72B | 14.80B | 13.40B |
| GainsLossesNotAffectingRetainedEarnings | -182.00M | -136.20M | -153.70M | -164.90M |
| OtherEquityAdjustments | -182.00M | -136.20M | -153.70M | -164.90M |
| TreasuryStock | 2.98B | 2.98B | 2.98B | 2.98B |
| RetainedEarnings | 20.55B | 19.26B | 17.63B | 16.47B |
| AdditionalPaidInCapital | 863.10M | 569.40M | 302.50M | 73.30M |
| CapitalStock | 100.00K | 100.00K | 100.00K | 100.00K |
| CommonStock | 100.00K | 100.00K | 100.00K | 100.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 11.18B | 11.33B | 12.05B | 11.17B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 7.83B | 5.80B | 8.61B | 7.89B |
| OtherNonCurrentLiabilities | 748.50M | 732.30M | 781.10M | 944.20M |
| NonCurrentDeferredLiabilities | 507.60M | 190.50M | 641.80M | 334.70M |
| NonCurrentDeferredTaxesLiabilities | 507.60M | 190.50M | 641.80M | 334.70M |
| LongTermDebtAndCapitalLeaseObligation | 6.58B | 4.88B | 7.19B | 6.61B |
| LongTermCapitalLeaseObligation | 290.40M | 334.50M | 400.00M | 333.00M |
| LongTermDebt | 6.29B | 4.55B | 6.79B | 6.28B |
| CurrentLiabilities | 3.35B | 5.53B | 3.43B | 3.27B |
| OtherCurrentLiabilities | 838.40M | 746.90M | 10.80M | |
| CurrentDebtAndCapitalLeaseObligation | 1.75B | 150.00M | 999.10M | |
| CurrentDebt | 1.75B | 150.00M | 999.10M | |
| OtherCurrentBorrowings | 1.75B | 150.00M | 999.10M | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 375.80M | 375.80M | 335.10M | 395.60M |
| PayablesAndAccruedExpenses | 2.97B | 3.40B | 2.95B | 2.13B |
| CurrentAccruedExpenses | 2.43B | 2.43B | 2.29B | 1.38B |
| Payables | 546.80M | 972.50M | 660.70M | 751.40M |
| TotalTaxPayable | 114.80M | 548.30M | 257.40M | 259.90M |
| AccountsPayable | 432.00M | 424.20M | 403.30M | 491.50M |
| TotalAssets | 29.44B | 28.05B | 26.84B | 24.55B |
| TotalNonCurrentAssets | 20.47B | 20.59B | 19.99B | 14.76B |
| OtherNonCurrentAssets | 750.60M | 560.50M | 745.00M | 1.53B |
| NonCurrentDeferredAssets | 292.50M | 324.20M | 928.60M | 1.23B |
| NonCurrentDeferredTaxesAssets | 292.50M | 324.20M | 928.60M | 1.23B |
| InvestmentsAndAdvances | 431.90M | 0.00 | 0.00 | 705.70M |
| OtherInvestments | 1.53B | 1.94B | ||
| InvestmentinFinancialAssets | 431.90M | 0.00 | 0.00 | 705.70M |
| AvailableForSaleSecurities | 431.90M | 705.70M | 892.00M | |
| GoodwillAndOtherIntangibleAssets | 15.67B | 16.17B | 14.58B | 7.60B |
| OtherIntangibleAssets | 9.18B | 9.69B | 8.36B | 1.85B |
| Goodwill | 6.49B | 6.48B | 6.22B | 5.75B |
| NetPPE | 3.32B | 3.54B | 3.73B | 3.70B |
| AccumulatedDepreciation | -2.93B | -2.67B | -2.40B | -2.17B |
| GrossPPE | 6.25B | 6.21B | 6.13B | 5.87B |
| Leases | 143.50M | 137.80M | 135.70M | 107.70M |
| ConstructionInProgress | 163.10M | 308.40M | 975.40M | 888.80M |
| OtherProperties | 265.40M | 356.40M | 420.00M | 403.90M |
| MachineryFurnitureEquipment | 3.32B | 3.24B | 2.80B | 2.67B |
| BuildingsAndImprovements | 2.14B | 1.96B | 1.60B | 1.59B |
| LandAndImprovements | 216.70M | 202.40M | 202.40M | 202.40M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 8.97B | 7.46B | 6.86B | 9.79B |
| OtherCurrentAssets | 1.12B | 752.50M | 1.18B | 1.42B |
| Inventory | 2.17B | 2.46B | 2.53B | 1.34B |
| InventoriesAdjustmentsAllowances | -21.10M | 0.00 | ||
| OtherInventories | -21.10M | |||
| FinishedGoods | 200.40M | 187.90M | ||
| WorkInProcess | 751.90M | 814.00M | ||
| RawMaterials | 413.20M | 349.60M | ||
| Receivables | 1.87B | 1.87B | 2.10B | 2.14B |
| AccountsReceivable | 1.87B | 1.87B | 2.10B | 2.14B |
| AllowanceForDoubtfulAccountsReceivable | -3.00M | -2.20M | -2.40M | -2.30M |
| GrossAccountsReceivable | 1.87B | 1.87B | 2.10B | 2.14B |
| CashCashEquivalentsAndShortTermInvestments | 3.82B | 2.38B | 1.05B | 4.89B |
| OtherShortTermInvestments | 807.20M | 0.00 | 0.00 | 1.47B |
| CashAndCashEquivalents | 3.01B | 2.38B | 1.05B | 3.42B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 1.97B | 2.52B | 1.24B | 1.14B |
| RepurchaseOfCapitalStock | 0.00 | 0.00 | -750.00M | -1.80B |
| RepaymentOfDebt | -1.75B | -650.00M | -809.90M | -1.00B |
| IssuanceOfDebt | 1.73B | 0.00 | 997.20M | 0.00 |
| CapitalExpenditure | -235.40M | -359.80M | -311.40M | -243.20M |
| InterestPaidSupplementalData | 264.10M | 245.40M | 252.20M | 262.50M |
| IncomeTaxPaidSupplementalData | 864.00M | 355.10M | 740.70M | 262.50M |
| EndCashPosition | 3.01B | 2.38B | 1.05B | 3.42B |
| BeginningCashPosition | 2.38B | 1.05B | 3.42B | 2.26B |
| EffectOfExchangeRateChanges | 101.90M | -67.70M | 35.10M | -55.70M |
| ChangesInCash | 531.60M | 1.39B | -2.40B | 1.21B |
| FinancingCashFlow | -301.90M | -683.50M | 149.30M | -1.75B |
| CashFlowFromContinuingFinancingActivities | -301.90M | -683.50M | 149.30M | -1.75B |
| NetOtherFinancingCharges | -275.00M | -2.20M | 6.30M | 6.80M |
| ProceedsFromStockOptionExercised | -10.00M | -31.30M | -44.30M | -1.90M |
| NetCommonStockIssuance | 0.00 | 0.00 | -750.00M | -1.80B |
| CommonStockPayments | 0.00 | 0.00 | -750.00M | -1.80B |
| NetIssuancePaymentsOfDebt | -16.90M | -650.00M | 187.30M | -1.00B |
| NetLongTermDebtIssuance | -16.90M | -650.00M | 187.30M | -1.00B |
| LongTermDebtPayments | -1.75B | -650.00M | -809.90M | -1.00B |
| LongTermDebtIssuance | 1.73B | 0.00 | 997.20M | 0.00 |
| InvestingCashFlow | -1.37B | -799.20M | -4.10B | 1.58B |
| CashFlowFromContinuingInvestingActivities | -1.37B | -799.20M | -4.10B | 1.58B |
| NetOtherInvestingChanges | 42.90M | -4.70M | -11.30M | 24.40M |
| NetInvestmentPurchaseAndSale | -1.18B | 144.70M | 2.36B | 222.50M |
| SaleOfInvestment | 79.70M | 144.70M | 7.50B | 3.67B |
| PurchaseOfInvestment | -1.26B | 0.00 | -5.14B | -3.45B |
| NetBusinessPurchaseAndSale | 0.00 | -668.00M | -6.14B | 990.30M |
| SaleOfBusiness | 0.00 | 406.80M | 788.10M | 990.30M |
| PurchaseOfBusiness | 0.00 | -1.07B | -6.93B | 0.00 |
| NetIntangiblesPurchaseAndSale | -81.60M | -117.50M | -34.40M | -2.90M |
| SaleOfIntangibles | 0.00 | 88.60M | 0.00 | 0.00 |
| PurchaseOfIntangibles | -81.60M | -206.10M | -34.40M | -2.90M |
| NetPPEPurchaseAndSale | -153.80M | -153.70M | -277.00M | 342.30M |
| SaleOfPPE | 0.00 | 0.00 | 582.60M | 0.00 |
| PurchaseOfPPE | -153.80M | -153.70M | -277.00M | -240.30M |
| OperatingCashFlow | 2.20B | 2.88B | 1.55B | 1.38B |
| CashFlowFromContinuingOperatingActivities | 2.20B | 2.88B | 1.55B | 1.38B |
| ChangeInWorkingCapital | -1.06B | -155.20M | -648.70M | -890.30M |
| ChangeInOtherWorkingCapital | -1.21B | -100.20M | -372.90M | -234.30M |
| ChangeInPayablesAndAccruedExpense | 171.10M | 24.60M | -201.60M | -113.40M |
| ChangeInAccruedExpense | 171.10M | 24.60M | -201.60M | -113.40M |
| ChangeInInventory | -64.70M | -273.80M | -130.90M | -320.20M |
| ChangeInReceivables | 42.10M | 194.20M | 56.70M | -222.40M |
| ChangesInAccountReceivables | 102.70M | 222.30M | 61.30M | -203.40M |
| OtherNonCashItems | 456.90M | 519.20M | 304.10M | 335.30M |
| StockBasedCompensation | 290.80M | 291.20M | 264.20M | 254.10M |
| ProvisionandWriteOffofAssets | 167.60M | |||
| AssetImpairmentCharge | 60.80M | 60.20M | 0.00 | 119.60M |
| DeferredTax | 361.60M | -158.10M | -305.80M | -168.60M |
| DeferredIncomeTax | 361.60M | -158.10M | -305.80M | -168.60M |
| DepreciationAmortizationDepletion | 779.90M | 673.20M | 494.80M | 518.40M |
| DepreciationAndAmortization | 779.90M | 673.20M | 494.80M | 518.40M |
| AmortizationCashFlow | 507.10M | 386.50M | 240.60M | 246.30M |
| AmortizationOfIntangibles | 507.10M | 386.50M | 240.60M | 246.30M |
| Depreciation | 272.80M | 286.70M | 254.20M | 272.40M |
| OperatingGainsLosses | 19.30M | 12.80M | 277.10M | -1.75B |
| EarningsLossesFromEquityInvestments | 0.00 | 0.00 | -2.60M | -34.90M |
| GainLossOnInvestmentSecurities | 19.30M | 101.40M | 277.10M | 265.90M |
| GainLossOnSaleOfPPE | 0.00 | -88.60M | 0.00 | -503.70M |
| GainLossOnSaleOfBusiness | 0.00 | 0.00 | -1.51B | 0.00 |
| NetIncomeFromContinuingOperations | 1.29B | 1.63B | 1.16B | 2.96B |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BIIB
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|